Table 1.
Baseline characteristics.
| HF N = 46 |
Control N = 20 |
p Value | |
|---|---|---|---|
| Age, mean (SD) | 68 (8) | 52 (9) | 5 × 10−9 |
| Male, n (%) | 41 (89) | 10 (50) | 0.0006 |
| European | 29 (63) | 16 (80) | 0.18 |
| AF | 10 (22) | 0 (0) | N/A |
| HTN | 21 (46) | 0 (0) | N/A |
| T2Dm | 9 (20) | 0 (0) | N/A |
| ACEi/ARB | 37 (80) | 0 (0) | N/A |
| Beta blocker | 39 (85) | 0 (0) | N/A |
| MRA | 14 (3) | 0 (0) | N/A |
| Statin | 29 (63) | 0 (0) | N/A |
| Frusemide | 10 (22) | 0 (0) | N/A |
| EF bp mean (SD) | 39% (10 | 57% (5) | 8 × 10−9 |
| GLS | −13% (0.04) | −21% (0.05) | 3 × 10−8 |
| NTproBNP (pmol/L) | 115 (124) | 8 (10) | 0.0002 |
AF = atrial fibrillation, HTN = hypertension, T2DM = type 2 diabetes, ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, MRA = mineralocorticoid receptor antagonist, EF bp = ejection fraction by Simnpson’s biplane, GLS = global longitudinal strain.